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Introduction  
Evolution of Antibiotics and Antibiotic Resistance in environmental and soil bacteria    
Antibiotic resistance genotypes evolved over two billion years ago (1).  Antibiotic 
resistance genes were acquired by gram-positive bacteria through horizontal gene transfer 
approximately 800 million years ago (1). Human use of antibiotics, including clinical use and 
agricultural production, has exacerbated the development of antibiotic resistance since the 
1940’s when industrial production of antibiotics began. Examination of plasmids isolated from 
pre-1940 bacterial collections contain few resistance genes suggesting that the presence of these 
genes may significantly contribute to the alteration of microbiota. This also demonstrates that 
human use of antibiotics is linked to the spread of antibiotic resistance (2).  
Multiple theories have been suggested to explain the evolution of antibiotics and antibiotic 
resistance genes in bacteria. One theory is that these genes evolved both as a form of protection 
against competing microorganisms in the environment and for protection against self-made 
antibiotics. An alternative hypothesis is that low levels of antibiotic production will support 
functions such as communication between bacteria as well as gene expression in some cases 
(1,3). 
Antibiotic Classes and Mechanisms 
Antibiotics can be bacteriostatic or bactericidal in action with different chemical 
structures, and target a variety of cellular mechanisms based on antibiotic class (4). The 
quinolone class of antibiotics target both DNA gyrase and topoisomerase IV(5) during DNA 
replication through the formation of a reversible quinolone-topoisomerase-DNA complex that 
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prevents DNA replication. This prevents of the formation of phosphodiester bonds (4) and incites 
an SOS stress response and cell filamentation (5). 
Macrolides are a class of antibiotics synthesized by non-ribosomal peptide synthetases during 
secondary metabolism and are typically bacteriostatic in action. Macrolides bind to ribosomal 
RNA machinery at the nascent peptide exit tunnel (NPET) during translation. This results in 
inhibition of bacterial growth by interrupting the elongation of new polypeptides (6,7,8). 
Erythromycin, isolated from Saccharopolyspora erythraea is an example of the macrolide class of 
antibiotics (6,7).    
β-lactam antibiotics such as penicillin and methicillin are also synthesized by non-ribosomal 
peptide synthetases (1). The chemical name for β-lactam is 2-azetidinone and is known as “the 
enchanted rings” for its safety in use. The β-lactam ring is the minimum structural component 
needed for antibiotic activity. (Figure 1a). The chemical structure of a β-lactam is a four-
membered, cyclic amide ring with a carbonyl group consisting of three carbons, one nitrogen, 
and five hydrogen atoms (C3NH5). Methicillin (C17H20N2O6S) is a semi-synthetic, β-lactamase 
resistant, and bactericidal derivative of penicillin that has been in use since 1960 (Figure 1b).  
β-lactam rings are structurally similar to the D-ala-D-ala linkages between N-acetylmuramic acid 
subunits in peptidoglycan (Figure 1c). β-lactam rings target and covalently bond to 
transpeptidase active sites of Penicillin-binding proteins (PBPs), causing inhibition of cell wall 
synthesis (8,9). There are two classes of high molecular weight PBPs, aPBPs (class A) and bPBPs 
(class B) as well as low molecular weight PBPs. Class A PBPs contain glycosyltransferase and 
transpeptidase activity. The glycosyltransferase domain polymerizes glycan elements and 
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transpeptidase activity cross-links them to create D-Ala-D-Ala linkages between N-acetylmuramic 
acid subunits. Currently, the only known function of bPBPs is transpeptidase activity. 
Peptidoglycan bonds are cleaved by low molecular weight PBPs and are also targeted by β-
lactams (8). Inhibition of peptidoglycan synthesis by β-lactamases leads to weakening of the cell 
wall followed by cell lysis (8).       
Antimicrobial Resistance 
Bacteria resist antibiotics through modification of the target, modification or hydrolysis 
of the antibiotic, or through efflux pumps. Efflux pumps may be single substrate specific or have 
the ability to export multiple substrates of unrelated classes (10, 11). The latter of these efflux 
systems can confer resistance to multiple antibiotics with the gain of a single gene, affording 
multidrug resistance to bacteria that possess them (10).  Single point mutations within antibiotic 
resistance genes may generate modification of antibiotic targets. Alterations in the target confer 
antibiotic-resistance while allowing cellular function to continue (11). In addition, the creation of 
“mosaic” genes may occur as a result of uptake of environmental DNA that provide antibiotic 
resistance through alteration of antibiotic target proteins (11).   
The gain of homologous genes that produce an altered antibiotic target provides an additional 
mechanism of resistance.  Staphylococcal Cassette Chromosome mecA (SCCmecA) encodes for 
Penicillin-binding-protein 2a (PBP2a), which allows Staphylococcus to continue peptidoglycan 
synthesis in the presence of β-lactam antibiotics targeting Penicillin-binding-proteins (PBPs) (11). 
Enzymatic activity of phosphotransferases, acetyltransferases, and nucleotidyl transferases alter 
aminoglycoside antibiotics such as Gentamycin. This activity produces steric hindrance and 
prevents antibiotic molecules from complexing with target proteins. This results in antibiotic 
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resistance in host bacteria such as Campylobacter coli. A strain of C. coli identified in China 
contains a novel genomic island encoding for phosphotransferases, acetyltransferases, and 
nucleotidyl transferases.  Aminoglycoside antibiotics are used to treat Campylobacter infections 
(11). 
Bacteria are ubiquitous to most environments and prokaryotic genes that encode for antibiotic 
synthesis and antibiotic resistance pathways are ancient and may have evolved over a time span 
of billions of years. Bacteria isolated within Lechuguilla Cave, New Mexico for over four million 
years were found to be reservoirs for antibiotic resistance genes. Surprisingly, resistance to 
modern semi-synthetic antibiotics such as daptomycin was identified within the genomes of 
some of the culturable isolates (2). The development of resistance to antibiotics has become a 
worldwide challenge affecting over two million individuals and causing over twenty-three 
thousand deaths annually (12).   In 2013, the World Economic Forum (WEF) stated that, “arguably 
the greatest risk…to human health comes in the form of antibiotic-resistant bacteria.  We live in 
a bacterial world where we will never be able to stay ahead of the mutation curve.  A test of our 
resilience is how far behind the curve we allow ourselves to fall.” (13) 
Exposure of pathogens to antimicrobials has not been limited to the “antibiotic era” of the past 
100 years, which began with the development of Salvarsan as a treatment for Syphilis during the 
early 1900’s. Bald’s Leechbook, a 1000-year-old English medical text, contains a plant-based 
recipe to treat a “wen” (thought to be a sty). This recipe was recently tested by Harrison, F., et 
al. (2015) and was shown to have bactericidal activity against pathogens such as Staphylococcus 
aureus (14). Also, traditional Chinese medicine has used qinghaosu, extracted from Artemisia 
species, to treat illnesses for thousands of years (14,16). Finally, honey has been used as an 
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antimicrobial by Egyptians and was used in armed combat during the 20th century for 
antimicrobial treatment of wounds (15).  
Methicillin-Resistant Staphylococcus aureus (MRSA)  
Staphylococcus aureus are Gram-positive cocci that commonly inhabit the skin of 20% of 
individuals and nasal passages of 33% of the human population, as well as being carried by some 
animals (18,19). Resistance to methicillin was acquired by Staphylococcus aureus in 1961, just 
one year after this drug was introduced as the first semi-synthetic antibiotic developed to treat 
Staphylococcal infections (18).  Now, 80% of all Staphylococcus aureus isolates are resistant to 
penicillin and many have developed resistance to methicillin and vancomycin (20). Vancomycin 
is seen as a “last resort” antibiotic for the treatment of Methicillin-resistant Staphylococcus 
aureus (MRSA) and its use has led to several MRSA strains that now carry vancomycin resistance 
genes. These strains are usually multi-drug resistant as well, and pose a major threat in the 
treatment of staphylococcal infections (21,22). 
Resistance to methicillin was originally acquired in a hospital setting and MRSA is now the most 
commonly recognized antibiotic-resistant microorganism in the USA and is known as Healthcare-
Associated methicillin-resistant Staphylococcus aureus (HA-MRSA) (17). Some clones of HA-
MRSA have spread globally, including the archaic clone ST250/SCCmecI and strain N315 
discovered in Japan, where they have evolved and adapted in different regions of the world 
(3,20). Approximately 70% of HA-MRSA infections worldwide are caused by 6 pandemic clones. 
These MRSA strains carry SCCmec types I-III (3,17). 
Community-Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) emerged after HA-
MRSA and was identified in 1981 with the detection of SCCmec type IV (17). The Centers for 
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Disease Control defines CA-MRSA as, “MRSA from outpatients (patients in the community) with 
no history of hospitalization, surgery, dialysis, or indwelling percutaneous medical devices and 
catheters in the past one year or inpatients isolated within 48 hours after hospital admission.” 
CA-MRSA infections typically occur in family and athletic groups, and in disaster relief evacuees. 
Infections occur in healthy individuals through skin-to-skin contact as skin and soft tissue 
infections (SSTIs), and from deep tissue infections such as carbuncles and cellulitis.  The most 
common strain causing CA-MRSA found in the United States is USA300 (3). 
Before acquiring resistance to methicillin, Staphylococcus aureus may be methicillin-susceptible 
and is designated Methicillin-Susceptible Staphylococcus aureus (MSSA) (17,23,24). MSSA gains 
resistance to methicillin through acquisition of a plasmid containing the mobile genetic element 
SCCmecA (23). Acquisition of β-lactam resistance occurs when SCCmecA is inserted into the 
chromosome of MSSA (23).  MecA encodes for Penicillin- Binding Protein 2a (PBP2a or PBP2’ in 
the United Kingdom) (19). SCCmec also contains site-specific cassette chromosome recombinases 
A, B, or C (ccrA, ccrB, or ccrC) and their surrounding open reading frames (ORF’s) (23).  
J regions are non-essential, sometimes called “junkyard” or “joining” regions, and carry 
supplementary antimicrobial resistance elements. There are three identified J regions for 
SCCmec: J1, which is located between the right junction of the chromosome to the ccr genes; J2, 
located between the ccr genes and the mec complex; and J3, located between the mec complex 
and the left portion of SCCmec (19). 
Currently there are eight types of Sccmec elements that have been described. Classification is 
based upon a combination of one of five ccr gene complexes (1 through 5) and one of four mec 
gene complexes (A, B, C1, and C2) (23). 
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Novel antibiotics  
The necessity for research and development of novel antibiotics has increased as 
antibiotic-resistant bacteria have spread during the “antibiotic era”. Conversely, pharmaceutical 
development of novel antibiotics has decreased significantly in the past 30 years (25,26). 
Insufficient economic incentives are the most common reason given for decreasing research and 
development (25), which can span ten to twelve years before release to market occurs (27).   
Historically, pharmaceutical companies base their income on a price-per-volume model with an 
expectation of higher pricing and/or higher volumes sold to increase sales profits and a return on 
investment for research funds expended. Generic antibiotics, which typically have lower 
consumer costs and are still effective in some circumstances, compete with novel antibiotics in 
clinical settings. This competition typically maintains lower costs overall for both generic and 
novel antibiotics and creates a situation where the return on investment for research and 
development of new drugs is difficult to achieve, further reducing incentives for future 
development (28). Low profits related to antibiotic sales combined with limited markets and 
limited government research funding has caused pharmaceutical companies to reallocate 
funding of antibiotic research and development to areas that will provide greater revenue. By 
2013, several major pharmaceutical companies had reduced or discontinued antibiotic research 
and development altogether (25).  
Non-ribosomal peptide synthetases 
Non-ribosomal peptide synthetases (NRPSs) are large, multimodular enzymes produced 
by bacteria and fungi. Through condensation reactions of amino acids in secondary metabolism, 
NRPSs produce nonribosomal peptides (NRPs) (42,43,44) that consist of approximately five 
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hundred different monomers, including fatty acids, alpha-hydroxy acids, and non-proteinogenic 
amino acids (42,45). There are three catalytic domains required for synthesis of NRP’s and are 
crucial to peptide formation. The first is an adenylation (A) domain that activates amino acids, 
the second is a thiolation or peptidyl carrier protein (PCP) which elongates the peptide chain, and 
the third are condensation (C) domains that act on amino acids.  Termination and release of 
peptide chains occurs catalytically at a thioesterase domain (TE) (4,46), which is located at a 
termination module.  Some examples of NRP’s include the antibiotic daptomycin and the 
immunosuppressant drug cyclosporin (42).  
Variovorax paradoxus EPS 
Variovorax paradoxus EPS is a ubiquitous Gram-negative beta-proteobacterium of the 
family Comamonadaceae. Many members of genus Variovorax have been identified as 
constituents of various soils and pond waters through rRNA gene-based detection (29,30,31,32). 
Catabolic pathways of genus Variovorax allow it to breakdown toxins and/or complex carbon 
compounds in polluted environs and this activity has been the subject of bioremediation studies. 
Known anabolic activities of genus Variovorax include synthesis of the enzymes N-acyl-D-amino 
acid amidohydrolase (function unknown), D-aminase (hydrolyses amino acid amides), and α-
Methyl serine aldolase (catalyzes α-Methyl-serine to D-alanine and α-hydroxymethylserine to D-
serine) (35,37).  Currently there are no strains of V. paradoxus that have been identified as 
pathogenic (32). 
Variovorax paradoxus EPS strain has previously been identified as producing an 
exopolysaccharide (30). Exopolysaccharide production combined with type IV pilus production 
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results in the conversion of V. paradoxus EPS from a sessile to a mobile growth phenotype when 
the correct physical and nutrient conditions are present (30). 
The genome of V. paradoxus EPS consists of a circular chromosome that is 6,550,056 bases in 
length with a G+C content of 66.48% (38). Previous genetic analysis has identified three loci 
suspected to encode for a NRPS.  These loci are Varpa_4324--27, Varpa_4519, and Varpa_2887-
-88. The function of Varpa_4519 has been characterized for surfactant production 
(34).  Varpa_2887--88 is an amino acid adenylation domain (41). 
In a study completed by C.W. Johnston, et al. (39), a novel non-ribosomal peptide synthetase-
polyketide synthase (NRPS-PKS) gene cluster was identified in Variovorax paradoxus P4b (gene 
cluster identified as Var3 through Var7). The products of this gene cluster are novel metabolites, 
Variobactin A and Variobactin B. Variobactin A has a molecular formula of C47H84N11O7 and a 
mass-to-charge ratio (m/z) of 1074.60. In a separate study, C. Kurth, et al. (40) studied the plant 
associated bacterium Variovorax boronicumulans BAM-48 to identify a NRPS-PKS gene cluster 
whose product, Variochelin A, is an acyl-peptide and functions as a photoreactive lipopeptide 
siderophore. The molecular formula and mass-to-charge values of Variochelin A are equivalent 
to Variobactin A. In their same study, C. Kurth et al. (40) identified a Variovorax paradoxus EPS 
gene cluster whose function is also a siderophore. This gene cluster consists of genes that 
correspond to Varpa_4324-27 but are different in both size and organization in comparison to 
gene clusters identified in both V. paradoxus P4b and V. boronicumulans BAM-48. 
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Hypothesis 
Preliminary research has shown that Variovorax paradoxus EPS has anti-staphylococcal 
activity in liquid and solid co-culture. Solid plating of co-culture of V. paradoxus EPS and 
Staphylococcus aureus has determined that this activity is replicable. Based on activity in broth 
culture, we predict that the activity is mediated by a small, soluble molecule. Anti-staphylococcal 
activity of Wild type and V. paradoxus EPS 𝚫4519 on 0.5% YE agar with embedded S. aureus 
AH1710 supports the concept of a soluble molecule as the agar acted as a physical barrier 
between V. paradoxus EPS and S. aureus colonies. The small molecule is suspected to be the 
product of a non-ribosomal peptide synthetase (NRPS) (34). Genetic analysis of V. paradoxus EPS 
has identified three loci that are suspected to express the molecule of interest. Preliminary data 
failed to detect expression at two of the three identified loci and a mutation at this third locus 
continues to produce anti-staphylococcal activity.  
I hypothesize that the microbial agent is expressed at a different locus or loci that have yet been 
identified. These products are in-part or wholly responsible for the production of the microbial 
agent and will be controlled by exposure to Staphylococcus aureus. The use of a V. paradoxus 
EPS Δ 4519 transposon library to identify phenotypic expression and the genes responsible for 
this expression, will allow us to identify the genetic component responsible for expression of the 
small molecule. 
We used direct phenotypic and genetic methods to identify the active molecule and the 
genes involved in its production. 
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Methods and materials  
Media and Culture Conditions 
Bacterial strains, relevant genotypes, and culture conditions that included antibiotics 
required for standard growth conditions used in this study can be found in Table 1 below.  
Overnight cultures of Wild type Variovorax paradoxus EPS and V. paradoxus EPS 𝚫4519 
were grown in selective media (Table 1). Overnight cultures of Staphylococcus aureus strain 
AH1710=S. aureus RN4220 + pCM29 CmR (PsarA_RBSsod_SGFP) or S. aureus strain AH3849=S. 
aureus LAC(AH1263) +pHC48 CmR (pCM29_dsRed) were grown in Tryptic Soy broth (TSB) + 
Chloramphenicol 25 mg/L. Overnight cultures of E. coli S17-1 λpir (pOT182:Tn5) were grown in 
LB broth  + Tetracycline 25 mg/L or Gentamycin 10 mg/L. 
All cultures were incubated at 30℃ with shaking (New Brunswick Scientific Classic Series C24 
Incubator Shaker) for 24-48 hours. For quantitative assays, cultures were incubated at 30℃ with 
shaking (New Brunswick Scientific Classic Series C24 Incubator Shaker) for 24- 72 hours. 
Cultures grown with antibiotics were washed 2 times in selective media (Table 1), centrifuged at 
4000 x g for 12 minutes, and re-suspended in selective media (Table 1).  
T-streak method to determine anti-staphylococcal activity 
 Wild type V. paradoxus EPS and S. aureus AH1710 or S. aureus AH3849 were inoculated 
as perpendicular streaks onto 0.5% YE agar (5 g/L Yeast Extract + 0.5% agar). Plates were 
incubated 480 hours and examined every 24 hours for determination of anti-staphylococcal 
activity.  
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RNA extraction of Wild Type V. paradoxus EPS  
Wild type V. paradoxus EPS in FWS media and co-culture Wild type V. paradoxus EPS/S. 
aureus AH1710 in FWS media were diluted to density OD600 of 0.2 to 0.3 (Thermo Spectronic, 
Genesys 20, Model number 4001/4) to meet density requirements of the Qiagen protocol. Both 
culture and co-culture were stored in Qiagen RNAlater RNA Stabilization Reagent (Catalog No./ID: 
76104) and if necessary, frozen at -20℃ for future use. For an approximately equivalent number 
of Wild type V. paradoxus EPS cells, 500 µl of culture and 1.0 ml of co-culture were used. RNA 
extraction was completed using Qiagen RNeasy Mini kit (Catalog No.74104) (48) with 15 mg/ml 
Lysozyme in TE buffer (10 mM Tris, 1 mM EDTA) increased to 5 mg/ml. The volume of reagents 
used were: 200 µl of 5 mg/ml Lysozyme in TE buffer, 700 μl Buffer RLT with β-mercaptoethanol, 
and 500 μl 100% ethanol. Promega DNAse treatment (5 μl RQ1 RNase-Free DNase, 2 μl RQ1 
RNase-Free DNase 10X Reaction buffer, 63 μl molecular-grade water) was completed on column. 
Extracted RNA was re-suspended in 50 μl RNase-free water (48). 
Phenol/Chloroform/Isoamyl alcohol 25:24:1 pH 8.0 (Fisher Scientific, Catalog No. BP17521-100) 
extraction was completed with 50 μl extracted RNA (modified from N.E. Biolabs protocol and 
Short Protocols in Molecular Biology, 5th Edition pg 2-3). Extracted RNA was mixed with 20 μl of 
5 M ammonium acetate, and diluted with RNase-free water to a volume of 500 μl. An equal 
volume of Phenol/Chloroform/Isoamyl alcohol (PCI) was added and briefly vortexed to mix, 
followed by centrifugation at maximum speed for 15s. The aqueous layer was transferred to a 
clean tube. This process was repeated twice followed by chloroform extraction using the same 
protocol twice. The extracted RNA was precipitated by addition of two volumes of absolute 
ethanol and incubation at -20°C for a minimum of 30 minutes. The precipitation was centrifuged 
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at maximum speed for 10 minutes and the supernatant was removed. The pellet was rinsed with 
70% ethanol followed by centrifugation at maximum speed for 5 minutes. Ethanol was carefully 
removed to prevent disturbing the pellet, followed by air drying. RNA was re-suspended in 40 μl 
RNase-free H2O. Samples were stored at -20°C or below if not used immediately. 
Reverse Transcription of Wild type V. paradoxus EPS  
Reverse transcription was completed using Promega GoScript Reverse Transcription 
System (Catalog No. #A5000). The protocol was followed as written using the following 
component volumes, 2.0 μl experimental RNA, 2.0 μl random primers (500 µg/ml, 1.0 μl 
luciferase (100 pg/μl), 5.0 μl Nuclease-Free Water, 4.0 μl GoScript 5X Reaction Buffer, 3.2 μl 
MgCl2, 1.0 μl PCR Nucleotide Mix, 0.5μl Recombinant RNasin Ribonuclease Inhibitor, and 1.0 μl 
GoScript Reverse Transcriptase.   
Expression analysis of anti-staphylococcal activity of Variovorax paradoxus EPS 
Real-time qPCR using was completed using Wild type V. paradoxus EPS cDNA and Wild 
type V. paradoxus EPS/S. aureus AH1710 co-culture cDNA at 0 and 46 hours to examine 
expression of Varpa_2887-88, Varpa_4524-27, and Varpa_4519 (Applied Biosystems 
StepOnePlus Real-time PCR system v2.2.2). A 40 cycle, three-step run method was used with hold 
temperature at 95.0℃ for 10 minutes. Temperature cycles for Cycle and Melt curve stages were 
95℃ for 15 seconds followed by 59.0℃ for one minute. Primers for qPCR were tested for 
efficiency using Wild type V. paradoxus EPS genomic DNA for Varpa_2887-88, Varpa_4324-27. 
This determined the most compatible forward and reverse primer sets for each RNA sequence 
(Refer to Table 2 for final primer sets used).  
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Quantitative analysis of anti-staphylococcal activity 
Overnight cultures of Wild type or V. paradoxus EPS 𝚫4519 in Freshwater Succinate (FWS) 
media (54) were washed one time in fresh media and re-suspended to a density at OD600 of 0.2 
to 0.3 (Thermo Spectronic, Genesys 20, Model number 4001/4). The S. aureus AH1710 was 
washed and re-suspended in FWS media at an OD600 to create a 2:1 density ratio with V. 
paradoxus EPS. Each culture type and a 1:2 co-culture was incubated at 30℃ for 72 hours.  At 
approximately 24-hour intervals, the CFU’s in each culture were determined by dilution plating. 
S. aureus AH1710 culture and co-culture were spot plated onto Tryptic Soy Agar (TSA) and V. 
paradoxus EPS was spot plated onto YE agar. Culture CFU was determined in this manner at 0, 
24, 48, and 72 hours. All plates were incubated at 30℃ for 24 to 48 hours. For CFU quantification, 
six spots of 5 µl culture or co-culture for each dilution value were plated in three replicate series. 
CFU’s were counted after 24 hours incubation for S. aureus AH1710 and 48 hours incubation for 
Wild type or V. paradoxus EPS 𝚫4519.   
Embedded S. aureus AH1710 with Wild type or V. paradoxus EPS 𝚫4519 
Experimentation with S. aureus AH1710 at density OD600 0.3 (Thermo Spectronic, Genesys 
20, Model number 4001/4) was embedded in 0.3% YE agar and spot or spread plated with Wild 
type V. paradoxus EPS at density OD600 0.5 allowed for examination of bactericidal activity over 
240 hour post inoculation .  
To determine if viable S. aureus AH1710 colonies in areas of minimal growth and 
fluorescence were resistant to V. paradoxus EPS, quantitative analysis of a randomly chosen 
viable S. aureus AH1710 colony was completed. Replicated assays determined these S. aureus 
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AH1710 were vulnerable to the anti-staphylococcal molecule at similar rates of previous 
quantitative analysis and that Green Fluorescent Protein expression was maintained. 
Analysis of V. paradoxus EPS activity on embedded S. aureus AH1710 with pour-over plating 
Overnight cultures of Wild type V. paradoxus EPS in YE broth or V. paradoxus EPS 𝚫4519 
in YE broth + Kanamycin 50 mg/L were washed one time and re-suspended to a density at OD600 
of approximately 0.3 (Thermo Spectronic, Genesys 20, Model number 4001/4). An overnight S. 
aureus AH1710 culture was washed twice in YE broth and re-suspended to a density at OD600 of 
approximately 0.5 (Thermo Spectronic, Genesys 20, Model number 4001/4). Embedded S. aureus 
AH1710 plates were created using cell culture diluted to 10-3. This was combined with YE broth 
at a 1:5 ratio. This S. aureus AH1710/YE broth mixture was combined 1:50 with 0.5% YE agar and 
plated at 15 ml per plate.  
Wild type or V. paradoxus EPS 𝚫4519 was diluted to 10-4. This dilution was added at a 1:5 ratio 
with YE broth. This mixture was spot plated centrally at 5 µl onto embedded S. aureus AH1710 
plates and allowed to dry at room temperature. Once dry, 5 ml of 0.5% YE agar was poured over 
inoculated plates and incubated at 30℃ for 24 hours and at room temperature thereafter. Plates 
were examined every 24 hours to identify V. paradoxus EPS colonies displaying anti-
staphylococcal activity.  
Creation of Variovorax paradoxus EPS 𝚫4519 transposon library   
The creation of a V. paradoxus EPS 𝚫4519 mutant transposon library used bi-parental 
mating of E. coli S17-1 λpir (pOT182:Tn5, Figure 2 below) as the donor strain and V. paradoxus 
EPS 𝚫4519 as the recipient strain. The donor strain was grown in LB agar + Gentamicin 10 mg/L 
broth and incubated at 30℃ for 24 hours. The recipient was grown in YE + Kanamycin 50 mg/L 
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broth and incubated at 30℃ for 24 hours. Each culture was washed 2 times, centrifuged at 4000 
x g for 12 minutes, and re-suspended in YE broth. Each culture density was normalized at OD600 
to 1.0 (Thermo Spectronic, Genesys 20, Model number 4001/4), followed by spot plating of a 
mixture containing 100 µl of each culture onto YE agar + 10 mM MgSO4 and incubated for 24 
hours at 30℃. The mixture was scraped from plates in 1X PBS and stored as 1 ml aliquots 
containing 15% glycerol in microcentrifuge tubes frozen at −80°C for future use.  
Transconjugated V. paradoxus EPS 𝚫4519 contain Kanamycin resistance (from 𝚫4519 
construction), and Tetracycline resistance (from parental strain E. coli S17-1 λpir (pOT182:Tn5). 
This allowed for selection screening of transconjugated V. paradoxus EPS 𝚫4519 on YE agar + 
Kanamycin 50 mg/L + Tetracycline 25 mg/L. The V. paradoxus EPS 𝚫4519 and E. coli mixture was 
spread plated and incubated at 30℃ for 48 hours. Only colonies of transconjugated V. paradoxus 
EPS 𝚫4519 would survive plating with both antibiotics.  
Transconjugated V. paradoxus EPS 𝚫4519 colonies were scraped from plates in 1X PBS and stored 
as 1 ml aliquots containing 15% glycerol in microcentrifuge tubes frozen at −80°C for future use. 
Each 1 ml of culture was determined to have approximately 10,200 CFU/ml of transconjugants. 
Confirmation of transconjugation of V. paradoxus EPS 𝚫4519 by Blue-White Screening 
Plasmid pOT182 contains a promoterless lacZ gene, allowing for blue-white screening to 
confirm successful transconjugation of 𝚫 Varpa_4519 V. paradoxus EPS. Colonies grown on YE 
1.5% agar + Kanamycin 50 mg/L + Tetracycline 25 mg/L were picked onto YE agar + 40 µl X-gal 
and incubated at 30℃ for 48 hours.  
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V. paradoxus EPS 𝚫4519 transposon screening  
Co-cultures of V. paradoxus EPS 𝚫4519 transposon library or Wild type V. paradoxus EPS 
transposon library, and S. aureus AH1710 were grown on YE agar to isolate colonies that over 
and under expressed the molecule of interest. The V. paradoxus EPS 𝚫4519 transposon library 
was brought to a density of OD600 of 0.000006 (Thermo Spectronic, Genesys 20, Model number 
4001/). S. aureus AH1710 was brought to a density OD600 of 0.0005 (Thermo Spectronic, Genesys 
20, Model number01/4). A 1:1 co-culture was spread plated at 100 µl onto approximately one-
hundred YE agar plates and incubated at 30℃ for 24-48 hours. Colonies that were isolated 
included the presence of or lack of a mucoid phenotype, a clear perimeter or no perimeter 
surrounding a transposon mutant colony, and unusual pigmentation.  
Spot plate screening of transposon mutants   
S. aureus AH1710 was grown overnight in TSB + chloramphenicol 25 (25 mg/L). This 
culture was washed two times in YE broth, resuspended to OD600 0.3 (Thermo Spectronic, 
Genesys 20, Model number 4001/4) and 100 µL was spread plated onto YE agar and TSA. Plates 
were air dried before spot plating occurred. V. paradoxus EPS 𝚫4519 transposon or Wild Type V. 
paradoxus EPS transposon cultures at a density of OD600 of 1.0 (Thermo Spectronic, Genesys 20, 
Model number 4001/4), were spot plated onto the S. aureus AH1710 lawns. Plates were be 
incubated at room temperature or 30℃ for 24 hours.  
Optimal density of S. aureus AH1710 for phenotypic expression and zone of inhibition 
formation by V. paradoxus EPS Δ4519         
                                                       
Optimal density was determined using 1:2 and 1:10 dilutions of S. aureus AH1710 OD600 
0.3 plated as a lawn onto YE agar and TSA and allowed to air dry. V. paradoxus EPS Δ4519 was 
spotted at 5µl onto S. aureus AH1710 and incubated at 30°C or room temperature overnight. 
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Plates were examined for zone of inhibition formation to determine optimal S. aureus AH1710 
density.  
Identification of phenotypic expression and zone of inhibition formation in V. paradoxus EPS 
Δ4519 transposon mutants 
 
To reexamine the effect of incubation temperature and density of S. aureus AH1710, the 
76 selected transposon mutants of interest were spot plated onto a lawn of S. aureus AH1710 to 
determine phenotypic expression and zone of inhibition. The optimal density of S. aureus AH1710 
at OD600 0.003 was spread at 100 µl onto YE agar and TSA and allowed to air dry. Plates were 
incubated at room temperature and examined 24-hours post inoculation for identification of 
zone of inhibition formation, mucoid phenotype production, and additional phenotypes of 
interest (Refer to Tables 5 and 6 below). 
Production of chemically competent cells 
 A colony of E. coli Top 10 F’ cells was inoculated into 1 ml SOB-Mg growth media (Bacto 
Tryptone 20 g/L, Bacto Yeast Extract 5 g/L, 10 mM 1M NaCl, 2.5 mM 1M KCl) and incubated at 
37°C with shaking (New Brunswick Scientific Classic Series C24 Incubator Shaker) overnight. At 
mid-log phase of growth (OD600 density of ~0.3), 500 µl of overnight culture was inoculated into 
50 mls of SOB-Mg growth media and incubated at 37°C with shaking (New Brunswick Scientific 
Classic Series C24 Incubator Shaker) until the culture grew to OD600 density ~0.3. This 50-ml 
culture was divided equally into two 50 ml sterile polypropylene tubes and placed in ice for 10 
minutes. Cultures were centrifuged at 2500 rpm for 14 minutes at 4°C to pellet cells and the 
supernatant discarded. Pelleted cells were gently re-suspended in 8.3 ml of CCMB (10 mM 
Potassium acetate 1M pH 7, glycerol 100 g/L, CaCl2 ·2H20 11.8 g/L, 2.5 mM MgCl2 ·6H20) followed 
by incubation on ice for 20 minutes. Cultures were centrifuged at 2500 rpm for 10 minutes at 4°C 
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and the supernatant discarded. Pellets were re-suspended in 2 ml of CCMB and aliquoted on ice 
followed by storage at -80°C (49). 
Genomic DNA extraction 
Genomic DNA was extracted from V. paradoxus EPS Δ4519 transposon mutants using 
Wizard Genomic DNA Purification Kit with protocol as written (50). Genomic DNA was stored at 
4°C.  
 Rescue Cloning of V. paradoxus EPS Δ4519 transposon mutants    
Rescue cloning of transposon mutants that displayed phenotypes of interest was 
completed using protocols described by Pehl M, et al. (36) with the following alterations: 10 U 
HindIII (Promega) restriction enzyme was used for digestion of genomic DNA. After one-hour 
incubation at 37°C, the product was spiked with an additional 1 U of HindIII restriction enzyme 
and incubated for an additional one hour at 37°C to ensure complete digestion.  
Ligation of the digestion product was completed using T4 ligase (Promega). The length of time 
for heat-shock was increased to one minute and SOC recovery media was increased to 450 µl per 
50 µl cells. Cells were plated onto LB agar + Tetracycline 25 mg/L and incubated at 37°C overnight. 
Cultures of successfully ligated E. coli were grown overnight in LB broth + Tetracycline 25 mg/L. 
Plasmids were extracted using Promega Wizard SV Minipreps DNA Purification System (51) and 
Sanger sequenced at Retrogen Inc., San Diego, CA (Refer to Table 5 below). Sequencing results 
were compared to published V. paradoxus EPS genome data (38). 
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Results 
T-streak evaluation of Anti-staphylococcal activity 
Current studies of anti-staphylococcal activity began with T-streak plating of Wild type V. 
paradoxus EPS and S. aureus AH1710 or S. aureus AH3849 onto YE agar and incubated at 30℃ 
for 480 hours. T-streak analysis demonstrated Wild type Variovorax paradoxus EPS spread rapidly 
through S. aureus AH1710 streaks which displayed a corresponding decrease in fluorescence. 
This provided qualitative analysis of a phenotypic response of Wild type V. paradoxus EPS to the 
presence of S. aureus (Figures 3 and 4.  
Real time qPCR  
Real-time qPCR (RT-qPCR) using Wild type V. paradoxus EPS RNA extracted from culture 
and co-culture with S. aureus AH1710 at zero and 46 hours was performed to examine expression 
of Varpa_2887-88, Varpa_4524-27, and Varpa_4519 to determine the locus or loci responsible 
for expression of the anti-staphylococcal molecule.  
Preliminary results of RT-qPCR indicate that Varpa_4519 is expressed by Wild type V. paradoxus 
EPS when exposed to S. aureus in liquid co-culture from zero to 46 hours, but Wild type V. 
paradoxus EPS liquid culture minimally expressed Varpa_4519 for the same time period (Figure 
5). Expression of Varpa_2887-88 and 4324-27 could not be detected.  
Quantitative analysis of anti-staphylococcal activity in liquid co-culture 
Quantitative analysis of anti-staphylococcal activity was completed using Wild type or V. 
paradoxus EPS 𝚫4519, and S. aureus AH1710 in both culture and co-culture. All cultures were 
incubated in FWS media and sampled at approximately 24-hour periods to for viable plate counts 
(Figures 6-9). FWS is a minimal media broth that provides succinate as a carbon source and NH4Cl 
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as a nitrogen source. Exponential growth of V. paradoxus EPS is possible with these limited 
nutrient resources. In a preliminary time course assay, it was found that S. aureus populations 
subsist in FWS, but did not grow in density. This variation in growth rates of V. paradoxus EPS 
and S. aureus allow for measurement of anti-staphylococcal activity without concern for 
separation of growth and death rates during analysis. These assays allowed for comparison of 
Wild type and V. paradoxus EPS 𝚫4519 to determine if anti-staphylococcal activity occurred in 
the mutant strain and if the rate of anti-staphylococcal activity differed in comparison of wild 
type and mutant strains. Figure 6 demonstrates CFU formation of Wild type V. paradoxus EPS 
and S. aureus AH1710 in co-culture and S. aureus AH1710 in culture.  Growth of Wild type V. 
paradoxus EPS in culture and co-culture indicate that over 70 hours, CFU’s remain consistent 
between groups. In comparison, S. aureus AH1710 CFU’s decrease approximately 99% at 70 hours 
in co-culture, but remains consistent between groups in mono-culture (Figure 7). Figures 8 and 
9 demonstrate similar CFU formation of V. paradoxus EPS 𝚫4519 and S. aureus AH1710 in co-
culture and S. aureus AH1710 in culture. Comparison of anti-staphylococcal activity between Wild 
type V. paradoxus EPS and V. paradoxus EPS 𝚫4519 demonstrates that S. aureus AH1710 in co-
culture with V. paradoxus EPS 𝚫4519 decreased more significantly at 48 hours than in co-culture 
with Wild type V. paradoxus EPS.   
Preliminary results of RT-qPCR for Wild type V. paradoxus EPS indicate Varpa_4519 is expressed 
in the presence of Staphylococcus aureus (Figure 5). In co-culture, V. paradoxus EPS 𝚫4519 
exhibits anti-staphylococcal activity, indicating Varpa_4519 is not required for anti-
staphylococcal activity. When examined together, results for RT-qPCR of Wild type V. paradoxus 
EPS and quantitative analysis of Varpa_4519 suggest there is either overexpression of precursors 
25 
 
to Varpa_4519 that are responsible in whole or part for the anti-staphylococcal activity, or 
exposure to S. aureus initiates a global recognition system that expresses the anti-staphylococcal 
molecule of interest. 
Embedded S. aureus AH1710 with Wild type or V. paradoxus EPS 𝚫4519 
Experimentation with S. aureus AH1710 embedded in 0.3% YE agar and spot or spread 
plated with Wild type V. paradoxus EPS allowed for examination of bactericidal activity over 240 
hour post inoculation (Figure 10). A variation to this protocol used embedded S. aureus AH1710 
with spot plated Wild type or 𝚫4519 with the addition of a 5 ml 0.5% YE agar overlay.  
To determine if viable S. aureus AH1710 colonies in these areas of minimal growth and 
fluorescence were resistant to V. paradoxus EPS, quantitative analysis of a randomly chosen 
viable S. aureus AH1710 colony was completed. Replicated assays determined that these S. 
aureus AH1710 were vulnerable to the anti-staphylococcal molecule at similar rates of previous 
quantitative analysis and that Green Fluorescent Protein expression was maintained (Figures 11 
and 12). 
Isolation of TN5 Transconjugated V. paradoxus EPS 𝚫4519 
Transconjugated V. paradoxus EPS 𝚫4519 will contain Kanamycin, Tetracycline, and 
Gentamicin resistance. This allowed for selection screening of transconjugated V. paradoxus EPS 
𝚫4519 on YE agar + Kanamycin 50 mg/L + Tetracycline 25 mg/L. Because E. coli does not grow on 
YE agar, we expected viable colonies of transconjugated V. paradoxus EPS 𝚫4519 only to grow 
on this agar with selected antibiotics. 
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Confirmation of transconjugation of V. paradoxus EPS 𝚫4519 
Plasmid pOT182 contains a lacZ gene, allowing for blue-white screening to confirm 
successful transconjugation of V. paradoxus EPS 𝚫4519. Successfully transconjugated colonies 
express 𝜷-galactosidase for this screening (Figure 13). 
Screening of V. paradoxus EPS 𝚫4519 transposon library 
Co-cultures of V. paradoxus EPS 𝚫4519 transposon library or Wild type V. paradoxus EPS 
transposon library, and S. aureus AH1710 were grown on approximately 100 YE agar plates to 
screen transposon mutants displaying phenotypes of interest, such as mucoid expression a clear 
perimeter surrounding a transposon mutant colony, or a change in pigmentation. A total of 206 
colonies were chosen for isolation and further study in combination with S. aureus AH1710.   
Spot plate screening of Variovorax paradoxus EPS Δ4519 transposon mutants 
Two-hundred six Variovorax paradoxus EPS Δ4519 transposon mutants were chosen for 
examination of anti-staphylococcal activity. These mutants were randomly assigned numbers 
from one to 97 and 100 to 208 for identification only. Phenotypic expression and zone of 
inhibition formation were identified for each transposon on TSA agar. Examples of phenotypes 
examined included V. paradoxus EPS Δ4519 transposon mutant colonies that leave remnants of 
S. aureus AH1710 as a hollow shell of green fluorescent protein (“ghosts of staph”, Figure 14 
below), with or without a dark ring at the perimeter (Figure 14 below), colonies with a hazy green 
or bright green ring at the perimeter (Figure 15 below), a change in pigment from yellow to 
creamy/white and mucoid colonies (Figure 16). Of the 206 transposon mutants, 76 were 
identified for further screening. Twenty-eight of these were selected for rescue cloning and 
Sanger sequencing in preparation for complementation (Refer to Table 4 below).  
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Optimal density of S. aureus AH1710 for phenotypic expression and zone of inhibition 
formation by V. paradoxus EPS Δ4519 
Plates spot plated to determine optimal density of S. aureus AH1710 were examined 24 
hours post incubation. It was determined that OD600 0.003 S. aureus AH1710 provided sufficient 
density for zone of inhibition formation by V. paradoxus EPS Δ4519 transposon mutants when 
plated onto YE agar and TSA (Figures 17 and 18 below).   
Identification of phenotypic expression and zone of inhibition formation in V. paradoxus EPS 
Δ4519 transposon mutants 
 
The 76 V. paradoxus EPS Δ4519 transposon mutants plated onto TSA at optimal density 
and room temperature or 30°C incubation displayed varied phenotypic expression and zone of 
inhibition production amongst the transposon mutants. A zone of inhibition greater than the Wild 
type V. paradoxus EPS and V. paradoxus EPS Δ4519 controls occurred in 18 V. paradoxus EPS 
Δ4519 transposon mutants (ten of these were chosen for Sanger sequencing). Zones of inhibition 
at both incubation temperatures were produced by 5 transposon mutants (5 sent for Sanger 
sequencing). Zones of inhibition less than or equal to the control strains were produced by 5 
transposon mutants (not sequenced). Please refer to Tables 3 through 7 below. Mucoid colonies 
at room temperature occurred in five transposon mutants and in six transposon mutants at 30°C 
incubation. Mucoid colonies in both room temperature and 30°C incubation occurred in one 
transposon only (Refer to Tables 3 through 7 below). 
Transformation Efficiency of Chemically Competent Cells 
 Transformation efficiency of chemically competent cells is 6.0 X 106 cfu/µg. 
Sanger sequencing   
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Sequencing results for the 28 V. paradoxus EPS Δ4519 transposon mutants selected for 
over or under expression of anti-staphylococcal activity. Published functions (58) indicated a 
widespread selection of genotypes that produced zones of inhibition and phenotypes of interest. 
Of interest is the identification of Varpa_1031, a transposon mutant without zone of inhibition, 
mucoid colony, and pigmented creamy/white. It is thought to be partially responsible for the 
production of Exopolysaccharide in V. paradoxus EPS. Also, transposon mutant 139 was identified 
as Varpa_4679 and Transposon mutant 96 as Varpa_4680. Together, these loci are known to 
express for exopolysaccharide production in Variovorax paradoxus EPS. Transposon mutants 164 
and 178 were identified as the same gene, Varpa_4665. A mutation in this gene produces a 
denser biofilm in culture, is not involved in swarming motility, and is currently under investigation 
as a regulator of global patterns of gene expression. 
Hypothetical proteins were identified for seven of the gene sequences (Refer to Tables 8 through 
11 below). 
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Discussion 
 
Hypothesis and Non-ribosomal peptide synthetases 
In our study of Variovorax paradoxus EPS, we have demonstrated that V. paradoxus EPS 
and V. paradoxus EPS Δ4519 have anti-staphylococcal activity in liquid and solid co-culture under 
various conditions. When plated with S. aureus AH1710, zones of inhibition are present after 
room temperature incubation. These zones are a classic indicator of antibiotic activity and their 
presence suggests the antimicrobial produced by V. paradoxus EPS is a small soluble molecule 
similar to known antibiotics. We predicted that a small molecule, the product of a non-ribosomal 
peptide synthetase, was responsible for anti-staphylococcal activity. Preliminary data suggested 
that three loci, Varpa_2887-88, Varpa_4524-27, and Varpa_4519 were putative candidates for 
expression of the small molecule.  Expression analysis of these loci indicated a lack of expression 
of Varpa_4519 in mono-culture at each time point, but significant expression in co-culture at 46 
hours. This suggests that Varpa_4619 is controlled at least in part by exposure to Staphylococcus 
aureus. Lack of expression by Varpa_2887-88 and Varpa-4524-27 suggests they are not involved 
in phenotype expression with exposure to S. aureus.  
Non-ribosomal peptide synthetases 
From our preliminary data, we expected a non-ribosomal peptide synthetase to be responsible 
for the production of the anti-microbial molecule, however expression analysis did not support 
this outcome. By screening the large number of colonies produced by our transposon library, it 
is conceivable, based upon the large size of the V. paradoxus EPS genome and the relative size of 
NRPS genomes, that if an NRPS was responsible for expression of phenotypes of interest, it would 
have been identified. It could be however, that our screen was insufficient in size or format, and 
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rescreening of this transposon library may yield results that identify expression by one or more 
NRPS.   
Establishment of Anti-Staphylococcal Activity 
To identify Variovorax paradoxus EPS and S. aureus colonies in co-culture, a gift of Green 
and Red Fluorescent Protein S. aureus was made from Alex Horswill, University of Iowa. This gift 
allowed for comparison of colony phenotypes and S. aureus viability in culture and co-culture as 
fluorescence diminished over time.  
Initial qualitative analysis was completed using T-streak plating of Wild type V. paradoxus EPS 
against S. aureus AH1710 or S. aureus AH3849 to determine if anti-staphylococcal activity was 
present. It was determined that fluorescence, and therefore cell viability, decreased almost 100% 
over the assay period. With these results, it was determined that screening assays for optimal 
growth conditions to induce anti-staphylococcal activity would need to be developed. 
Real-Time qPCR data led us to ask if Varpa_4519 was solely responsible for the anti-
staphylococcal activity. However, deletion of this locus did not result in a loss of the anti-
staphylococcal activity, indicating that Varpa_4519 was not solely responsible. To avoid the 
influence of S. aureus on Varpa_4519, it was decided to use a Wild Type Transposon mutant, 
Variovorax paradoxus EPS Δ4519, for further examination of anti-staphylococcal activity. In this 
study. 
We have shown on that anti-staphylococcal activity occurs on solid media, but its 
effectiveness as an anti-staphylococcal drug is unknown at this time. Once the molecule or 
molecules are identified, determination of toxicity levels may indicate a specified clinical use, 
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such as topical ointment. This may be an effective delivery system since many Staphylococcal 
infection occur on or through the skin.   
Screening for Optimal Growth Conditions 
At the inception of this study, growth conditions to promote expression of anti-
staphylococcal activity were unknown. To determine these conditions, assays were developed 
using various media in liquid and solid forms, and incubation temperatures in different ranges.   
Optimal results occurred when S. aureus was at density OD600 0.003, incubation occurred at room 
temperature and plating was completed on Tryptic Soy Agar. These results are in part 
contradictory to previous studies of which indicated that anti-staphylococcal activity does not 
occur on TSA at 30°C incubation but does occur on YE agar under the same conditions. It is 
currently not known why there is a significant change in expression when incubation occurs at 
different temperatures.  
During this study, we identified zone of inhibition formation using a dense inoculum of V. 
paradoxus EPS transposon mutants plated onto S. aureus AH1710 at a lower density than 
previously used in assays. This, combined with lower incubation temperature, provided growth 
conditions that allowed V. paradoxus EPS transposon mutants to grow at approximately the same 
rate as S. aureus AH1710, allowing us to observe the expressed inhibitory function. This result 
supports our hypothesis that V. paradoxus EPS produces a small molecule that inhibits or halts 
the growth of S. aureus AH1710. Alternatively, our results indicate that it is not clear if zone of 
inhibition formation is the result of relative growth rates, a change in anti-microbial expression, 
a change in staphylococcal susceptibility, or some combination of these effects. 
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Creation of a V. paradoxus EPS Δ4519 Transposon library 
Real-time qPCR results indicated that Varpa_4519 was expressed by V. paradoxus EPS in 
co-culture. To determine if Varpa_4519 was responsible in whole or in conjunction with 
additional gene sequences, a V. paradoxus EPS Δ4519 transposon library was created. This library 
provided the ability to screen for phenotypes that over or under-expressed for anti-
staphylococcal activity.  Twenty-eight transposon mutants that exhibited phenotypes of interest 
or a loss of these phenotypes were rescue cloned, Sanger sequenced, and compared to the V. 
paradoxus EPS genome for identification of both the locus and its function (53). Of these 
Transposon mutants, eleven did not produce mucoid colonies or zones of inhibition, and were 
pigmented creamy/white. Sequencing results indicate functions that range from hypothetical 
proteins to regulatory enzymes and transcriptional regulators. Of interest is the identification of 
Varpa_1031, thought to be partially responsible for the production of exopolysaccharide in V. 
paradoxus EPS.  
The remaining sixteen transposon mutants each produced a zone of inhibition at room 
temperature incubation. Zones of inhibition were not produced by Wild type V. paradoxus EPS 
and V. paradoxus EPS Δ4519 at 30°C incubation, but five of these eleven did so. The implications 
for this change in expression are currently unknown. Sequencing results indicate functions that 
also range from hypothetical proteins to regulatory enzymes and transcriptional regulators. Of 
interest are transposon mutants identified as Varpa_4679-80, members of a putative operon that 
expresses for Exopolysaccharide in V. paradoxus EPS. As identified was Varpa_4665 whose 
function is biofilm formation and is currently under investigation in the Orwin laboratory as a 
global regulator of phenotype. With disruption of either Varpa_4680 or Varpa_4665, we see an 
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increase level of biofilm formation and an increased level of anti-microbial activity. However, it 
is currently unknown if one or multiple compounds are responsible for observed anti-
staphylococcal activity on plates and in liquid culture. Our transposon library analysis has 
identified genes related to exopolysaccharide production and biofilm formation, but our findings 
do not conclusive show that antibiotic production is regulated by a system that also controls 
exopolysaccharide and biofilm formation. Our findings do suggest that their expression may 
overlap in some way.   
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Future Plans 
 
 Continued work for this study will use the following approaches: The V. paradoxus EPS 
Δ4519 transposon library will be re-screened under optimal conditions for S. aureus AH1710 
(density OD600 0.003 and room temperature incubation on TSA). This will allow for continued 
screening of transposon mutants that overexpress for anti-staphylococcal activity as well as the 
potential identification of a null transposon, a necessity for comparison of phenotypic expression 
and identification of locus or loci responsible for anti-staphylococcal activity. Rescue cloning will 
be completed by complementation of genes of interest identified previously. This will confirm 
the expression of desired phenotypes by V. paradoxus EPS Δ4519 transposon mutants. Finally, a 
comparison of Wild type V. paradoxus EPS transposon and V. paradoxus EPS Δ4519 transposon 
genotypes and comparable phenotypes may provide additional information that may lead to the 
identification of a global regulatory system putatively thought to be controlled in part by 
Varpa_4665. 
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Appendix 1: Figures 
 
   
   
Figure 1: Class 𝛽-lactam structures 
Left panel: Β-lactam ring structure (Chatterjee, S., Ahmed, M., & Wang, F., 2016)             
Middle panel: Methicillin (National Center for Biotechnology Information)                            
Right panel: Peptidoglycan 
(http://www.nature.com/nchembio/journal/v12/n7/full/nchembio.2109.html?WT.feed
_ name=subjects_chemical-tools) 
 
 
 
               
(https://shigen.nig.ac.jp/ecoli/strain/file/registryFile/pOT182.gif) 
Figure 2: Map of pOT182 
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a) 48 hours p.i.                 b) 192 hours p.i.              c) 480 hours p.i.              d) 220 hours p.i. 
Figure 3: T-streak evaluation anti-staphylococcal activity of Wild type V. paradoxus EPS and S. 
aureus AH1710 on 0.5% YE agar 
Wild type V. paradoxus EPS on 0.5% YE agar expresses a mucoid phenotype that can be viewed 
over time as it grows into and spreads throughout S. aureus AH1710. Green fluorescent protein 
expression diminishes over time as S. aureus AH1710 cells loose viability through the activity of 
V. paradoxus EPS. c. At 48 hours p.i. V. paradoxus EPS has spread through the S. aureus streak 
but florescence has not diminished significantly (Figure 3a). At 192 hours p.i., V. paradoxus EPS 
has continued to spread throughout S. aureus but fluorescence has become diminished (Figure 
3b). By 480 hours p.i., V. paradoxus EPS has spread beyond the border of S. aureus and there is 
minimal fluorescence at the outer edges only of S. aureus only Figure 3c). A control plate of S. 
aureus AH1710 at 220 hours demonstrates the fluorescence is maintained at a higher rate of 
expression compared to 192 hours plated with V. paradoxus EPS (Figure 3d). Images taken using 
UV lighting (Entela UVP UL3101-1) with a Panasonic DM-ZS1, 12X optical zoom, 25mm wide angle 
camera. 
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a) 48 hours p.i.                    b) 192 hours p.i.                c) 480 hours p.i.                d) 220 hours p.i. 
Figure 4: T-streak evaluation anti-staphylococcal activity of Wild type V. paradoxus EPS and S. 
aureus AH3849 on 0.5% YE agar  
Wild type V. paradoxus EPS with S. aureus AH3849 in a replicate T-streak experiment to Figure 5. 
The same mucoid phenotype can be seen spreading throughout S. aureus AH3849 with the same 
reduction in fluorescence of S. aureus AH3849 over 480 hours p.i. A control plate of S. aureus 
AH1710 at 220 hours demonstrates the fluorescence is maintained at a higher rate of expression 
compared to 192 hours plated with V. paradoxus EPS (Figure 4b). Images taken using UV lighting 
(Entela UVP UL3101-1) with a Panasonic DM-ZS1, 12X optical zoom, 25mm wide angle camera. 
 
 
A B  
Figure 5: RT-qPCR indicates expression of Varpa_4519 in co-culture only  
Zero-hour results indicate approximately equal expression of Varpa_4519 in mono- and co-
culture B) 46-hour results indicate approximately equal expression of Varpa_4519 in mono-
culture to 0 hour. 46-hour expression of Varpa_4519 in co-culture is significantly increased in 
comparison to mono-culture at 0 and 46 hours. Expression of Varpa_2887 and Varpa_4324 was 
not detected. A student’s unpaired t-test was performed to compare expression of Varpa_4519 
in culture and co-culture at 0 hour (p = 0.87) and 46 hours (p = 0.039).  
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Figure 6: Wild type V. paradoxus EPS and S. aureus AH1710 co-culture and S. aureus AH1710 
culture 
V. paradoxus EPS/S. aureus AH1710 (left side plates) and S. aureus AH1710 culture (right side 
plates). Anti-staphylococcal activity is evident over 70 hours on co-culture plates when compared 
to 70 hour S. aureus AH1710 plates. Images taken using UV lighting (Entela UVP UL3101-1) with 
a Panasonic DM-ZS1, 12X optical zoom, 25mm wide angle camera. 
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Figure 7: Wild type V. paradoxus EPS and S. aureus AH1710 Co-culture and S. aureus AH1710 
Quantitative Analysis 
A) Growth of Wild type V. paradoxus EPS culture and in co-culture over 70 hours B) Growth of 
S. aureus AH1710 culture and in co-culture over 70 hours. Results indicate anti-staphylococcal 
activity of V. paradoxus EPS occurs when in co-culture with S. aureus AH1710.  
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Figure 8: V. paradoxus EPS 𝚫4519 and S. aureus AH1710 co-culture and S. aureus AH1710  
A) 0 hour B) 22 hours C) 48 hours D) 71 hours dilution series comparison of co-cultured  
V. paradoxus EPS 𝚫4519/S. aureus AH1710 (left side plates) and S. aureus AH1710 culture (right 
side plates). Results suggest that expression of Varpa_4519 is not required for anti-
staphylococcal activity to occur. Images taken using UV lighting (Entela UVP UL3101-1) with a 
Panasonic DM-ZS1, 12X optical zoom, 25mm wide angle camera. 
 
A B  
Figure 9: V. paradoxus EPS 𝚫4519 and S. aureus AH1710 co-culture and S. aureus AH1710 
quantitative analysis 
A) Growth of V. paradoxus EPS 𝚫4519 in culture and co-culture over 67 hours B) Growth of S. 
aureus AH1710 culture and in co-culture over 70 hours. Results suggest that anti-staphylococcal 
activity occurs without expression of 𝚫4519 but does not exclude possible expression of related 
genes within this locus or interactions with currently unidentified loci.  
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Figure 10: Wild type Variovorax paradoxus EPS grown on embedded Staphylococcus aureus 
AH1710 
A) Wild type V. paradoxus EPS on 0.3% YE with S. aureus AH1710 embedded in agar 64h post 
inoculation.  Fluorescence indicates viable S. aureus AH1710 under 5 μl V. paradoxus EPS spotted 
onto agar B) Wild type V. paradoxus EPS on 0.3% YE with S. aureus AH1710 embedded in agar 
290h p.i.. A lack of fluorescence suggests that S. aureus AH1710 is no longer viable in the presence 
of V. paradoxus EPS. A Nikon Model CD-S microscope and an Andor Technology camera (model 
no. DR328G-CO2-SIL) was used for this image.  
 
Figure 11: Quantitative analysis of Wild type V. paradoxus EPS and S. aureus AH1710 isolated 
from minimal fluorescence  
A) 0 hour B) 23 hours C) 46 hours D) 71 hours p.i. for dilution series comparison of co-cultured 
Wild type V. paradoxus EPS and S. aureus AH1710 (left side plates) and S. aureus AH1710 culture 
(right side plates). S. aureus AH1710 was isolated from an area of minimal fluorescence. These 
staphylococci are vulnerable to anti-staphylococcal activity in co-culture with similar results to 
previous Wild type V. paradoxus EPS/S. aureus AH1710 quantitative analysis. Images taken using 
UV lighting (Entela UVP UL3101-1) with a Panasonic DM-ZS1, 12X optical zoom, 25mm wide angle 
camera. 
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A B  
Figure 12: Quantitative Analysis of potentially resistant S. aureus AH1710  
A) Growth of Wild type V. paradoxus EPS over 71 hours B) Growth of S. aureus AH1710 culture 
and in co-culture over 71 hours. These results demonstrate that S. aureus AH1710 isolated from 
areas of minimal colony formation and fluorescence have a similar level of susceptibility to S. 
aureus AH1710 grown from maintained culture. A control of Chloramphenicol 25 mg/L (Chlor 25) 
determined if S. aureus AH1710 resistance to this antibiotic provided additional resistance to V. 
paradoxus EPS in co-culture. 
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Figure 13: Confirmation of transconjugation of V. paradoxus EPS 𝚫4519 using blue white 
screening 
Thirty-seven colonies were picked at random from transconjugated V. paradoxus EPS 𝚫4519 onto 
YE 1.5% agar + X-gal. All colonies picked have β-galactosidase expression confirming successful 
transconjugation of pOT182 plasmid into V. paradoxus EPS 𝚫4519. Images taken with a Panasonic 
DM-ZS1, 12X optical zoom, 25mm wide angle camera. 
 
 
 
 
 
47 
 
A  B  
 
Figure 14: Examples of phenotypic variances of V. paradoxus EPS Δ4519 transposon 
mutants 
Image A) Remnants of Green Florescent Proteins in the coccoid shape of Staphylococcus 
aureus (“Ghosts of staph”) when plated with V. paradoxus EPS Δ4519 transposon 160 on YE 
agar 7 days p.i. (Transposon mutant 160 YE agar) Image B) A dark ring surrounding V. 
paradoxus EPS Δ4519 transposon 167 on YE agar 1 day p.i. (Transposon mutant 167 YE agar) 
 
 
 
A  B  
Figure 15: Examples of phenotypic variances of V. paradoxus EPS Δ4519 transposon mutants 
Image A) A hazy green ring surrounding V. paradoxus EPS Δ4519 transposon 160 on YE agar 3 
days p.i. (Transposon mutant 160 YE agar). Image B) A bright green ring surrounding V. 
paradoxus EPS Δ4519 transposon 87 on TSA seven days p.i. (Transposon mutant 87 TSA) 
48 
 
 
Figure 16: Examples of variation in pigmentation and mucoid colonies of V. paradoxus EPS Δ4519 
transposon mutants 
 V. paradoxus EPS Δ4519 transposon mutant 88 expresses normal pigmentation (red arrow). 
Transposon mutant 141 expresses a cream/white pigmentation (blue arrow). Transposon mutant 
160 expresses for mucoid colonies (green arrow). 
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A        b        B 
Figure 17: Zone of Inhibition formation at Room temperature and 30°C Incubation with OD600 
0.3 S. aureus AH170  
V. paradoxus EPS Δ4519 spot plated onto OD600 0.3 density S. aureus AH170. Images taken under 
a) white light and b) fluorescent lighting. Zones of inhibition do not form on TSA at room 
temperature or 30°C incubation temperatures at 24 hours post inoculation (images: 10-2 staph (0.3 
control) Mut 35 day 1 temp test 070517 and 10-2 staph (0.3 control) Mut 35 day 1 temp test 070517 UV)               
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A   B  
Figure 18: Zone of Inhibition formation at Room temperature and 30°C Incubation with OD600 
0.003 S. aureus  
V. paradoxus EPS Δ4519 spot plated onto OD600 0.003 density S. aureus AH170. Images taken 
under a) white light and b) fluorescent lighting. Zones of inhibition form on TSA at room 
temperature but not 30°C incubation at 24 hours post inoculation (10-2 staph V. paradoxus EPS Δ4519 
control and 10-2 staph V. paradoxus EPS Δ4519 control UV) 
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Appendix 2: Tables 
Table 1: Cell Types Used and their Maintenance 
Cell type Strain Source Growth media 
Variovorax 
paradoxus EPS 
Wild type Orwin laboratory YE agar (5 g/L + 1.5%) or YE broth (5 g/L)  
Freshwater Succinate broth (47) 
Variovorax 
paradoxus EPS  
𝚫4519 (KmR) Orwin laboratory YE agar (5 g/L + 1.5%) or YE broth (5 g/L) + 
Kanamycin 50 mg/L 
Freshwater Succinate broth (47) 
Staphylococcus 
aureus 
AH3849=S. aureus 
LAC(AH1263) +pHC48 
CmR (pCM29_dsRed) 
Alexander Horswill, 
University of Iowa  
Tryptic Soy Agar (40 g/L) or Tryptic Soy 
broth (30 g/L) + Chloramphenicol 25 mg/L  
 
staphStaphylococ
cus aureus 
AH1710=S. aureus 
RN4220 + pCM29 CmR 
(PsarA_RBSsod_SGFP) 
Alexander Horswill, 
University of Iowa  
Tryptic Soy Agar (40 g/L) or Tryptic Soy 
broth (30 g/L) + Chloramphenicol 25 mg/L  
Freshwater Succinate broth (47) 
Escherichia coli S17-1 λpir 
(pOT182:Tn5)  
DeShazer D., (1997) LB agar (25 g/L + 1.5%) or LB broth (25 g/L) 
+ Tetracycline 25 mg/L or Gentamycin 10 
mg/L 
YE broth (5g/L) 
Escherichia coli Top 10 F’ Daniel Nickerson, 
CSU San 
Bernardino 
LB agar (25 g/L + 1.5%) or LB broth (25 g/L) 
 
Incubation of inoculated plates was completed using a Fisher Scientific Isotemp Incubator. Incubation of Biosafety 
level 2 bacteria was completed using a New Brunswick Scientific Classic Series C24 Incubator Shake 
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Table 2: Primers for RT-qPCR 
Sequence name Forward Primer Reverse Primer 
2887  GCGTCTTCAACAACGTGCT ATCCTGGAACGAGAACATCG 
2888 CGCTGTGCGGGTGGTCGT GCGTTGCCTTCGTGGCG 
4324 CTGGATGCAGGAGACCTACC AGTTCAGGGTGGTGATCTGG 
4327 AGAGCGGGTGAAGGATGCG GCGGGGGCGAAGCGTT 
4519 GATTCCGTACCTCGACCTCA GTCGATGTTCCGGGTGTAGT 
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Table 3: Phenotype and Zone of Inhibition Formation for transposon mutants of interest not   
                sequenced 
 Zone of 
Inhibition 
formation  
Mucoid 
phenotype 
Additional 
notes  
 Zone of 
Inhibition 
formation 
Mucoid 
phenotype 
Additional 
notes 
 Tryptic Soy 
Agar 
Tryptic Soy 
Agar 
  Tryptic Soy 
Agar 
Tryptic Soy 
Agar 
 
Δ4519 
transposon 
RT 30°C RT 30°C   Δ4519 
transposon 
RT 30°
C 
RT 30°C  
4 9-10 
mm 
_ + _  78 _ _ _ _ RT and 30°C:  
Cream/white 
pigment 
7 7 
mm 
_ + +  93 
 
_ _ _ _ RT and 30°C:  
Cream/white 
pigment 
17 9-10 
mm 
_ + _  94 _ _ _ _ RT and 30°C:  
Cream/white 
pigment 
18 12 
 mm 
_ + _  95 _ _ _ _ RT and 30°C:  
Cream/white 
pigment 
21 _ _ _ _ RT and 30°C:  
Cream/white 
pigment 
97 _ _ _ _ RT and 30°C:  
Cream/white 
pigment 
24 _ _ _ _ RT and 30°C:  
Cream/white 
pigment 
107 _ _ _ _ RT and 30°C:  
Cream/white 
pigment 
29 _ _ _ _ RT and 30°C:  
Cream/white 
pigment 
122 _ _ _ _ RT and 30°C:  
Cream/white 
pigment 
36 _ _ _ _ RT and 30°C:  
Cream/white 
pigment 
133 _ _ _ _ RT and 30°C:  
Cream/white 
pigment 
41 _ _ _ _ RT and 30°C:  
Cream/white 
pigment 
138 _ _ _ _ RT and 30°C:  
Cream/white 
pigment 
42 _ _ _ _ RT and 30°C:  
Cream/white 
pigment 
140 _ _ _ _ RT and 30°C:  
Cream/white 
pigment 
49 _ _ _ _ RT and 30°C:  
Cream/white 
pigment 
147 _ _ _ _ RT & 30°C: 
pigmented 
creamy/white 
56 _ _ _ +  149 _ _ _ _ RT & 30°C: 
pigmented 
creamy/white 
57 _ _ _ _ RT and 30°C:  
Cream/white 
pigment 
153 9-10 
mm 
_ _ _ 30°C: 
pigmented 
green 
62  
N/A 
_  
N/A 
_ 30°C:  
Cream/white 
pigment 
154 _ _ _ _ 30°C: 
Creamy/white 
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Determination of anti-staphylococcal activity included production of mucoid phenotype and 
zone of inhibition formation. Phenotype production was most prominent on TSA plated with S. 
aureus AH1710 at density OD600 0.003.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
63  
N/A 
_  
N/A 
_ 30°C:  
Cream/white 
pigment 
159 _ _ _ _ RT & 30°C: 
pigmented 
creamy/white 
65  
N/A 
_  
N/A 
_ 30°C:  
Cream/white 
pigment 
166 12 
mm 
_ _ + RT: pigmented 
green 
67 _ _ _ _ RT & 30°C: 
pigmented 
creamy/white 
183 11-
12 
mm 
_ _ _ 30°C: 
pigmented 
green 
68 _ _ _ _ RT & 30°C: 
pigmented 
creamy/white 
185 13-
14 
mm 
_ _ + 30°C: 
pigmented 
green 
69 _ _ _ _ RT & 30°C: 
pigmented 
creamy/white 
189 6-7 
mm 
7-8 
mm 
_ + 30°C: 
pigmented 
green 
72 _ _ _ _ RT & 30°C: 
pigmented 
creamy/white 
191 13 
mm 
_ _ + 30°C: 
pigmented 
green 
74 15-  
16 
mm 
_ _ _ 30°C: 
pigmented 
green 
192 15 
mm 
8 
mm 
_ _ 30°C: 
pigmented 
green 
75 _ _ _ _  193 7-8 
mm 
7 
mm 
_ + 30°C: 
pigmented 
green 
76 _ _ _ _ RT and 30°C:  
Cream/white 
pigment 
194 11-
12 
mm 
_ _ +  
77 _ _ _ _ RT and 30°C:  
Cream/white 
pigment 
196 12 
mm 
_ + _  
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Table 4: Transposon mutants without Zone of Inhibition or Mucoid phenotypes                         
                 (RT & 30°C) selected for Sanger Sequencing 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Determination of anti-staphylococcal activity included production of mucoid phenotype  
and zone of inhibition formation. Phenotype production was most prominent on TSA  
plated with S. aureus AH1710 at density OD600 0.003.  
 
 
 Zone of 
Inhibition 
formation  
Mucoid 
phenotype 
Notes for V. paradoxus EPS Δ4519 
transposon phenotypes  
 Tryptic Soy 
Agar 
Tryptic Soy 
Agar 
 
 RT 30°C RT 30°C  
V. paradoxus 
EPS Wild type 
(WT) 
 
10 mm 
_ _ _ TSA at 30°C:  
Pigmented green and difficult to visualize.           
S. aureus viable under and outside spotted 
WT. 
V. paradoxus 
EPS Δ4519 
7-10 
mm 
_ + _ TSA at 30°C: Colonies are pigmented 
green 
 
Δ4519 
transposon:  
     
26 _ _ _ _ TSA at 30°C: Creamy/white pigment 
 
27 _ _ _ _ RT and 30°C:  Cream/white pigment 
 
37 _ _ _ _ RT and 30°C:  Creamy/white pigment 
 
39 _ _ _ _ Hazy green ring at perimeter of spots on 
TSA (Figure 19) 
TSA at 30°C: Cream/white pigment  
 
47 _ _ _ _ RT and 30°C:  Cream/white pigment 
 
50 _ _ _ _ Dark ring at perimeter of spots on TSA 
(Figure 18) 
TSA at 30°C:  Creamy/white pigment 
 
54 _ _ _ _ TSA at 30°C:  Creamy/white pigment 
 
60 _ _ _ _ TSA at 30°C:  Creamy/white pigment 
 
86 _ _ _ _ TSA at 30°C: Creamy/white pigment 
 
87 _ _ _ _ TSA at 30°C: Creamy/white pigment 
 
90 _ _ _ _ TSA at 30°C: Creamy/white pigment 
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Table 5: Transposon mutants with Zone of Inhibition greater than Wild type V. paradoxus EPS 
and V. paradoxus EPS Δ4519 and with or without Mucoid phenotypes (RT & 30°C) selected for 
Sanger Sequencing 
 
 
 
 
 Zone of Inhibition 
formation  
Mucoid 
phenotype 
Notes for V. paradoxus EPS Δ4519 transposon 
phenotypes  
 Tryptic Soy Agar Tryptic Soy Agar  
 RT 30°C RT 30°C  
V. paradoxus 
EPS  
Wild type (WT) 
 
10 mm 
_ _ _ TSA at 30°C:  
Pigmented green and difficult to visualize.           
S. aureus viable under and outside spotted WT 
V. paradoxus 
EPS Δ4519 
7-10 mm _ + _ TSA at 30°C: Colonies are pigmented green 
      
139   25 mm _ + _ TSA at 30°C Green pigment 
 
151 15 mm _ + _  
 
100  
15 mm 
_ + _ TSA at 30°C: S. aureus shriveled                   only 
under spotted transposon 
TSA at 30°C:  Green pigment 
 
162 15 mm _ _ _ TSA at 30°C: Green pigment 
 
96 15 mm _ _ _ TSA at 30°C:  Green pigment  
 
84 14-15 mm _ + + TSA at 30°C:  Green pigment 
 
169 14 mm _ + +  
 
91 12-13 mm _   + _  
 
164 12-13 mm _ + _ TSA at 30°C:  Green pigment 
 
161 11-12 mm _ + _ TSA at 30°C:  Green pigment 
 
Phenotype production was most prominent on TSA plated with S. aureus AH1710 at OD600 
0.003. Zones of Inhibition listed exceeded those of control strains Wild type V. paradoxus EPS 
and V. paradoxus EPS Δ4519. Not all phenotypes noted were identified on all V. paradoxus EPS 
Δ4519 transposon mutants. 
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Table 6: Transposon mutants with Zone of Inhibition at RT & 30°C and with or without 
Mucoid phenotypes selected for Sanger Sequencing  
Phenotype production was most prominent on TSA plated with S. aureus AH1710 at OD600 
0.003. Zones of Inhibition listed exceeded those of control strains Wild type V. paradoxus EPS 
and V. paradoxus EPS Δ4519. Not all phenotypes noted were identified on all V. paradoxus EPS 
Δ4519 transposon mutants. 
 
 
 
 
 
 
 
 
 
 
 Zone of Inhibition 
formation  
Mucoid 
phenotype 
Notes for V. paradoxus EPS Δ4519 transposon 
phenotypes  
 Tryptic Soy Agar Tryptic Soy Agar  
 RT 30°C RT 30°C  
V. paradoxus 
EPS  
Wild type (WT) 
 
10 mm 
_ _ _ TSA at 30°C:  
Pigmented green and difficult to visualize.           
S. aureus viable under and outside spotted 
WT. 
V. paradoxus 
EPS Δ4519 
7-10 mm _ + _ TSA at 30°C: Colonies are pigmented green 
      
104 20 mm    5-6 mm + +  
 
167 14-15 mm 7-8 mm  + +  
 
160  
13-14 mm 
 
12-13 mm 
+ 
 
+ “Ghosts of staph” (Figure 18) 
YE at 30°C: Pigmented green  
 
178 13-14 mm 13 mm _ +  
 
88 13 mm 12-13 mm  + 
 
+ TSA at 30°C Pigmented green  
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Table 7: Transposon mutants with Zone of Inhibition less than Wild type V. paradoxus EPS 
and V. paradoxus EPS Δ4519 and with or without Mucoid phenotypes (RT & 30°C) selected for 
Sanger Sequencing  
Phenotype production was most prominent on TSA plated with S. aureus AH1710 at OD600 
0.003. Zones of Inhibition listed were less than control strains Wild type V. paradoxus EPS and 
V. paradoxus EPS Δ4519. Not all phenotypes noted were identified on all V. paradoxus EPS 
Δ4519 transposon mutants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Zone of Inhibition 
formation  
Mucoid 
phenotype 
Notes for V. paradoxus EPS Δ4519 transposon 
phenotypes  
 Tryptic Soy Agar Tryptic Soy Agar  
 RT 30°C RT 30°C  
V. paradoxus 
EPS  
Wild type (WT) 
 
10 mm 
_ _ _ TSA at 30°C:  
Pigmented green and difficult to visualize.           
S. aureus viable under and outside spotted WT 
V. paradoxus 
EPS Δ4519 
7-10 mm _ + _ TSA at 30°C: Colonies are pigmented green 
      
19 8 mm _ + _   
 
79 8-9 mm _ + 
 
+  
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Table 8: Transposon mutants without Zone of Inhibition or Mucoid phenotypes (RT & 30°C)                
 selected for Sanger Sequencing 
Transconjugant 
number 
Gene sequence identified (52) Function (52) 
26 Varpa_5734 ABC-type phosphate/phosphonate 
transport system, ATPase component 
27 Varpa_5945  Transcriptional regulator, GntR family 
37 Varpa_4681  UDP-glucose 4-epimerase 
39 Varpa_0126 Hypothetical protein 
47 Varpa_3786 Hypothetical protein 
50 Varpa_3827  
 
Xylose isomerase domain-containing 
protein TIM barrel; AP endonuclease 2 
domain protein 
54 Varpa_2772 GumN family protein 
 
60 Varpa_5138 Hypothetical protein 
86 Varpa_4382  HNH nuclease  
87 Varpa_0777 glycosyl transferase family 2 
90 Varpa_1031 transcriptional regulator, Crp/Fnr family 
This subset of transposon mutants corresponds to those listed in Table 4 above. Transposon 
mutants 39 and 90 are similar in sequence location within the V. paradoxus EPS genome while 
the remaining are more widespread throughout the genome. Functions within this subgroup 
include three hypothetical proteins and protein functions that are currently known.  
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Table 9: Transposon mutants with Zone of Inhibition greater than Wild type V. paradoxus EPS 
and V. paradoxus EPS Δ4519 and with or without Mucoid phenotypes (RT & 30°C) selected for 
Sanger sequencing   
139 Varpa_4679 Sugar transferase 
151 Varpa_2880 2-hydroxy-3-oxopropionate reductase 
 
100 Varpa_3219  Polar amino acid ABC transporter, inner 
membrane subunit 
162 Varpa_4272 Hypothetical protein 
 
96 Varpa_4680  Glycosyl transferase group 1 
84—Insert 
between 
Vapra_4224  Patatin-like phospholipase 
 
 Varpa_4223 Nuclease (SNase domain-containing 
protein 
169 Varpa_3602  Protein of unknown function DUF6 
transmembrane 
91—Insert 
between 
Vapra_4224  Patatin-like phospholipase 
 
 Varpa_4223 Nuclease (SNase domain-containing 
protein 
164 Varpa_4665 Integral membrane sensor signal 
transduction histidine kinase 
161 Varpa_0944  NAD-dependent 
epimerase/dehydratase 
This subset of transposon mutants corresponds to those listed in Table 5 above. Transposon 164 
corresponds to transposon 178 in Table 10. Transposon pairs 84 and 91 are identical in gene 
sequence while transposon mutants 96 and 139 are sequential. The remaining transposon 
mutants are more widespread throughout the genome.  
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Table 10: Transposon mutants with Zone of Inhibition at RT & 30°C and with or without 
Mucoid phenotypes selected for Sanger sequencing   
104 Varpa_5846 Hypothetical protein 
167 Varpa_3390 Hypothetical protein 
160 Varpa_4127  Hypothetical protein 
 
178 Varpa_4665 Integral membrane sensor signal 
transduction histidine kinase 
88 Varpa_4548 Phosphoesterase 
 
This subset of transposon mutants corresponds to those listed in Table 6 above. Transposon 178 
corresponds to transposon 164 in Table 9. Functions within this subgroup include hypothetical 
proteins that are currently unknown.  
 
 
Table 11: Transposon mutants with Zone of Inhibition less than Wild type V. paradoxus EPS 
and V. paradoxus EPS Δ4519 and with or without Mucoid phenotypes (RT & 30°C) selected       
for Sanger sequencing 
19 Varpa_5160  Protein of unknown function DUF2134, 
membrane 
79 Varpa_2156  Polypeptide-transport-associated 
domain protein ShlB-type  
This subset of transposon mutants corresponds to those listed in Table 7 above and are           
unique in their gene sequence. 
 
 
 
